Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss.

I b a t fi ACKGROUND ome cases of unexplained recurrent spontaneous pregnancy oss have been proposed to arise from an undefined immuological barrier to normal placentation. One proposed treatent, active immunization with allogeneic leukocytes, benfits only 8% to 10% of treated couples, who cannot be elected by means of diagnostic testing (1). Another treatent, passive immunization with intravenous immunogloblin (IVIG), was promising in uncontrolled trials (2). IVIG, hich is human IgG prepared from pooled plasma, has a iverse antibody profile because thousands of donors conribute to the pool (3). IVIG treatment has now been evaluted in five randomized controlled trials (RCTs) (4–8). This ocument addresses the effectiveness of IVIG and the clincal implications of related publications.